top of page
Crystal Salt

Atticus in the News

Atticus Pharma was created via a spinout from Zylö Therapeutics [www.zylotherapeutics.com] in Q1 of 2024.  The drug-development programs that Atticus is pursuing are based on the Z-pod® sustained-release technology that originated at Albert Einstein College of Medicine and that was further developed at Zylö.  Some of the news items listed below were issued by Zylö pre-Atticus-spinout, but relate to Atticus and its various programs.

Atticus is born:
Zylö effects a spinout 

Atticus Pharma Inc. can unlock significant value by focusing on biopharma applications of Zylö's 'Powered by Z-pod®' sustained-release drug-delivery platform.

Blueprint

2023-10

Zylö accepted into NYU's Endless Frontier Labs [EFL] Mentorship Program to assist with spinout of Atticus and to provide guidance on vision and direction for Atticus

Only 78 of over 1,400 applicants accepted into this prestigious program that is designed to optimize each startup’s chance of scaling into a successful company.

bottom of page